• 1
    Seeff LC, DeGroff A, Tangka F, et al. Development of a federally funded demonstration colorectal cancer screening program [serial online]. Prev Chronic Dis. 2008;5:A64.
  • 2
    Tangka FK, Subramanian S, Bapat B, et al. Cost of starting colorectal cancer screening programs: results from 5 federally funded demonstration programs [serial online]. Prev Chronic Dis. 2008;5:A47.
  • 3
    DeGroff A, Holden D, Goode Green S, Boehm J, Seeff LC, Tangka F. Start-up of the colorectal cancer screening demonstration program [serial online]. Prev Chronic Dis. 2008;5:A38.
  • 4
    Seeff LC, Royalty J, Helsel WE, et al. Clinical outcomes from CDC's Colorectal Cancer Screening Demonstration Program. Cancer. 2013;119(suppl 15):2820-2833.
  • 5
    Centers for Disease Control and Prevention (CDC). Colorectal Cancer Clinical Data Elements. Atlanta, GA: CDC; 2012. Available at: [Accessed January 15, 2012.]
  • 6
    Vijan S, Hwang I, Inadomi J, et al. The cost-effectiveness of CT colonography in screening for colorectal neoplasia. Am J Gastroenterol. 2007;102:380-390.
    Direct Link:
  • 7
    Subramanian S, Bobashev G, Morris RJ. Modeling the cost-effectiveness of colorectal cancer screening: policy guidance based on patient preferences and compliance. Cancer Epidemiol Biomarkers Prev. 2009;18:1971-1978.
  • 8
    Pignone M, Russell L, Wagner J, eds. Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: Institute of Medicine and National Research Council; 2005.
  • 9
    Zauber A, Lansdorp-Vogelaar I, Wilschut J, van Ballegooijen M, Kuntz K. Cost-Effectiveness of DNA Stool Testing to Screen for Colorectal Cancer: Report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN and SimCRC Models. Rockville, MD: Agency for Healthcare Research and Quality; 2007.
  • 10
    Tangka FKL, Subramanian S, Beebe MC, Hoover S, Royalty J, Seeff LC. Clinical costs of colorectal cancer screening in five federally funded demonstration programs. Cancer. 2013;119(suppl 15):2863-2869.
  • 11
    Subramanian S, Ekwueme DU, Gardner JG, Bapat B, Kramer C. Identifying and controlling for program-level differences in comparative cost analysis: lessons from the economic evaluation of the National Breast and Cervical Cancer Early Detection Program. Eval Program Plann. 2008;31:136-144.
  • 12
    Anderson DW, Bowland BJ, Cartwright WS, Bassin G. Service-level costing of drug abuse treatment. J Subst Abuse Treat. 1998;15:201-211.
  • 13
    French MT, Dunlap LJ, Zarkin GA, McGeary KA, McLellan AT. A structured instrument for estimating the economic cost of drug abuse treatment: the Drug Abuse Treatment Cost Analysis Program (DATCAP). J Subst Abuse Treat. 1997;14:445-455.
  • 14
    Salome HJ, French MT, Miller M, McLellan AT. Estimating the client costs of addiction treatment: first findings from the client drug abuse treatment cost analysis program (Client DATCAP). Drug Alcohol Depend. 2003;71:195-206.
  • 15
    Drummond M, Schulpher M, Torrance G, O'Brien B, Stoddard G, eds. Methods for the Economic Evaluation of Health Care Programme. 3rd ed. Oxford, United Kingdom: Oxford University Press; 2005.
  • 16
    Castro G, Seeff L, Azrak F, et al. Outpatient colonoscopy complications in the CDC's Colorectal Cancer Screening Demonstration Program: a prospective analysis. Cancer. 2013;119(suppl 15):2849-2854.
  • 17
    US Bureau of Labor Statistics. Consumer Price Index for All Urban Consumers (CPI-U): Regions, by Expenditure Category and Commodity and Service Group. Washington, DC: US Bureau of Labor Statistics; 2008.
  • 18
    Swan J, Breen N, Graubard BI, et al. Data and trends in cancer screening in the United States: results from the 2005 National Health Interview Survey. Cancer. 2010;116:4872-4881.
  • 19
    Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:78-93.